<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007120</url>
  </required_header>
  <id_info>
    <org_study_id>RVT1601-RMP-01</org_study_id>
    <nct_id>NCT04007120</nct_id>
  </id_info>
  <brief_title>Open-label Study of Inhaled RVT-1601 in Preterm Infants</brief_title>
  <official_title>Open-label Study to Assess the Safety, Tolerability, Feasibility, and Pharmacokinetics of Inhaled RVT-1601 in Preterm Infants at High-risk for Long-term Respiratory Morbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respivant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Respivant Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Respivant Sciences Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth predisposes infants to greater risk for respiratory morbidities and the need
      for pulmonary care compared to term infants both in the short-term and long-term. In the
      short-term, preterm birth is a high risk factor for development of bronchopulmonary dysplasia
      (BPD), the second most common chronic pediatric respiratory disease after asthma. In the
      long-term, following discharge from the neonatal intensive care unit (NICU) and the hospital,
      preterm birth carries a high risk for respiratory morbidities (e.g., wheezing, cough, doctor
      visits, and hospitalizations for respiratory infections) and resource use, which in turn
      predisposes infants to the development of lung diseases in childhood and adulthood, including
      airway hyperresponsiveness, asthma, and chronic obstructive pulmonary disease (COPD). There
      is a significant unmet need for safe and efficacious approaches in the prevention and
      treatment of respiratory morbidities of prematurity.

      The study will be conducted in the neonatal intensive care unit (NICU) in preterm infants to
      determine safety, tolerability and lung delivery performance of RVT-1601, a new inhalation
      formulation of cromolyn sodium delivered via the eFlowÂ® Closed System (CS) nebulizer/face
      mask.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">May 29, 2020</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Pre-dose and 15 minutes post-dose</time_frame>
    <description>Assessment of heart rate (beats/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Pre-dose and 15 minutes post-dose</time_frame>
    <description>Assessment of systolic and diastolic blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in oxygenation</measure>
    <time_frame>Pre-dose and 15 minutes post-dose</time_frame>
    <description>Assessment of peripheral capillary oxygen saturation (SpO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>30 minutes post-dose</time_frame>
    <description>Assessment of peak plasma concentration of RVT-1601</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total urine excretion</measure>
    <time_frame>8 hours post-dose</time_frame>
    <description>Assessment of total urine content of RVT-1601</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Respiratory Morbidities of Prematurity (RMP)</condition>
  <arm_group>
    <arm_group_label>RVT-1601 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RVT-1601 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVT-1601</intervention_name>
    <description>Inhaled RVT-1601 administered once daily over two days</description>
    <arm_group_label>RVT-1601 Low Dose</arm_group_label>
    <arm_group_label>RVT-1601 Mid Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants between 32 weeks 0 days and 34 weeks 6 days of PMA

          -  Born between 24 weeks 0 days and 29 weeks 6 days of estimated GA

          -  Requiring minimal or no respiratory support (i.e., supplemental oxygen with &lt;2 liters
             per minute of nasal cannula flow acceptable)

          -  Body weight appropriate for gestational age

          -  Written informed consent obtained from at least one of the parents or legal guardians

        Exclusion Criteria:

          -  Requiring invasive or noninvasive respiratory support (e.g., mechanical ventilation,
             CPAP)

          -  Clinically unstable (i.e. unable to maintain SpO2 between 90-95 % , escalating
             respiratory support in the past 24 hours)

          -  Major congenital anomaly (chromosomal, renal, cardiac, hepatic, neurologic or
             pulmonary malformations)

          -  Significant cardiac disorder (i.e., pulmonary hypertension)

          -  History of major surgical procedure

          -  Any condition that would preclude receiving study drug or performing any study-related
             procedures

          -  Participation in any other investigational drug study

          -  History of hypersensitivity or intolerance to cromolyn sodium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>32 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women &amp; Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

